Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 14

Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD

Authors Albertson TE, Bowman WS, Harper RW, Godbout RM, Murin S

Received 16 December 2018

Accepted for publication 25 April 2019

Published 6 June 2019 Volume 2019:14 Pages 1251—1265

DOI https://doi.org/10.2147/COPD.S191845

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 4

Editor who approved publication: Dr Richard Russell


Timothy E Albertson,1,2 Willis S Bowman,1,2 Richart W Harper,1,2 Regina M Godbout,2,3 Susan Murin1,2

1Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, UC Davis, Sacramento, CA, USA; 2Department of Veterans Affairs, Northern California Health Care System, Mather, CA, USA; 3Department of Internal Medicine, Division of General Medicine, UC Davis, Sacramento, CA, USA

Abstract: The use of inhaled, fixed-dose, long-acting muscarinic antagonists (LAMA) combined with long-acting, beta2-adrenergic receptor agonists (LABA) has become a mainstay in the maintenance treatment of chronic obstructive pulmonary disease (COPD). One of the fixed-dose LAMA/LABA combinations is the dry powder inhaler (DPI) of umeclidinium bromide (UMEC) and vilanterol trifenatate (VI) (62.5 μg/25 μg) approved for once-a-day maintenance treatment of COPD. This paper reviews the use of fixed-dose combination LAMA/LABA agents focusing on the UMEC/VI DPI inhaler in the maintenance treatment of COPD. The fixed-dose combination LAMA/LABA inhaler offers a step beyond a single inhaled maintenance agent but is still a single device for the COPD patient having frequent COPD exacerbations and persistent symptoms not well controlled on one agent. Currently available clinical trials suggest that the once-a-day DPI of UMEC/VI is well-tolerated, safe and non-inferior or better than other currently available inhaled fixed-dose LAMA/LABA combinations for COPD.

Keywords: fixed-dose combination inhalers, long-acting beta2-adrenergic agonists, LABA, long-acting muscarinic antagonists, LAMA, COPD, umeclidinium bromide, vilanterol trifenatate


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]